Biopsy Devices Market

The global Biopsy Devices Market is valued at USD 6.1 Billion in 2023 and is projected to reach a value of USD 19.06 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 13.5% between 2024 and 2032. The market is driven by increase in cancer cases. The Union for International Cancer Control (UICC) projects over 35 million new cancer cases by 2050, marking a 77% rise from the approximately 20 million cases estimated in 2022.

Key Highlights

• Based on the Product, the Needle Based Biopsy Instruments category accounted for significant market share of 42.3% in 2023
• In 2023, by Application, Breast Cancer dominated the market with significant market share
• Based on End User, Hospitals and Breast Care Centers dominated the market with largest market share in 2023
• North America dominated the market with 42.3% market share in 2023
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period
• Governments and healthcare organizations are trying to reduce cancer treatment costs and promote regular screenings through awareness campaigns. For instance, the CDC's "Right to Know" campaign focuses on raising awareness about breast cancer screening for women with disabilities

Product Overview

​The Product segment is divided into Needle-Based Biopsy Instruments, Liquid Biopsy Instruments, Localization Wire, Biopsy Forceps, Procedure Tray, Biopsy Table, Other Biopsy Products. The Needle-Based Biopsy Instruments segment held the dominant share in 2023, accounting for significant market share of 42.3%.

Needle biopsies are an effective choice for patients and healthcare professionals worldwide because they are minimally invasive, usually quick, and cause no discomfort for the patient. The need for tissue samples has also increased due to the rising incidence of cancer and the necessity of early detection, particularly for lesions that are difficult to access with traditional techniques.

Application Overview

The Application segment is divided into Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Bone Marrow Cancer, Other Applications. In 2023, the Breast Cancer segment held largest share in the Biopsy Devices market.

Breast Cancer Segment’s dominance is attributed to the heightened focus on early detection and diagnosis of breast cancer, which has driven substantial demand for specialized biopsy devices. The increasing demand for these devices can be attributed to the high incidence of breast cancer as well as the continuous progress in diagnostic technologies. The market for breast cancer biopsy equipment is anticipated to hold the leading position as awareness and screening programs grow. This is because there is a pressing need for accurate and dependable diagnostic instruments in the fight against breast cancer.

Regional Overview

In 2023, the North America captured 42.3% of the revenue share.

• North America Biopsy Devices market is driven by the rise in cancer cases and the advancement of cutting-edge biopsy devices in the region are driving market growth. Innovations such as the U.S. Food and Drug Administration (FDA) approved Limaca Medical's Precision GI endoscopic ultrasound biopsy device with 510(k) clearance in September 2023 further boost market expansion.
• U.S. {Keyword}} market, valued at USD 2.11 Billion in 2023 to USD 6.75 Billion in 2032, is anticipated to grow at a CAGR of 13.8% from 2024 to 2032. The National Cancer Institute estimates that around 2,001,140 new cancer cases will be diagnosed in the U.S. in 2024. This increase in cancer incidence, combined with a robust healthcare system and supportive regulatory environment for advanced medical devices, is anticipated to drive market growth in the country.
• Europe was recognized as a promising area for growth. This is mostly because cancer is becoming more common and because it requires advanced equipment to diagnose and treat patients early. With nearly 3.7 million new cases and 1.9 million fatalities yearly, cancer is the second most common cause of death in the region, according to the World Health Organization.
• In the UK, the Biopsy Devices market is projected to expand significantly in the coming years. This growth is driven by the presence of major industry players, heightened awareness about preventive healthcare, and efforts to encourage early diagnosis and treatment. Notable initiatives include the 'Be Clear on Cancer' (BCoC) and 'Help Us Help You' (HUHY) public awareness campaigns.
• Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period, driven by the rising number of cancer cases, the growing need for advanced medical equipment to meet patient demands, and improvements in healthcare infrastructure in developing economies like China and India. According to the Global Cancer Statistics 2020, Asia accounts for half of all cancer cases and 58.3% of cancer deaths. To address this, governments in the region are implementing initiatives such as awareness campaigns and screening programs to improve diagnosis and treatment, which is likely to further boost market growth.
• In India, the Biopsy Devices market is anticipated to experience substantial growth due to the combined efforts of public and private sectors to enhance cancer diagnosis and treatment and the ongoing development of healthcare infrastructure. For example, in July 2024, the Sir H.N. Reliance Foundation Hospital introduced the MR Fusion Biopsy machine—the first of its kind in Maharashtra. This advancement is expected to improve cancer care in India and drive further growth in the market.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Minimally Invasive Techniques: There is a growing preference for minimally invasive biopsy procedures that reduce patient discomfort and recovery time while improving diagnostic accuracy
• Technological Advancements: Innovations such as robotic-assisted biopsy systems, advanced imaging techniques, and automated biopsy devices are enhancing precision and efficiency
• Integration with Digital Health: The integration of biopsy devices with digital health platforms and electronic medical records (EMRs) is improving data management, patient tracking, and overall workflow
• Personalized Medicine: The rise of personalized medicine is driving demand for biopsy devices that can provide detailed molecular and genetic information, aiding in tailored treatment plans
• Increased Focus on Cancer Diagnosis: As the incidence of cancer rises globally, there is heightened emphasis on developing biopsy devices that offer early and accurate cancer detection

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Rising prevalence of cancer drives the Biopsy Devices market

Globally, the number of cancer cases has risen significantly. GLOBOCAN estimates that the number of cancer cases is expected to reach 19.3 million by 2025. In the U.S., cancer is the second leading cause of death, accounting for nearly 1 in 4 deaths.

Cancer incidence is highest in more developed regions, while mortality rates are higher in less developed countries due to limited access to treatment and lower awareness of early detection benefits. The growing number of cancer patients is anticipated to boost the demand for biopsy procedures for diagnosing both malignant and benign tumors, driving market growth. The rapid increase in the elderly population and the rising cancer prevalence in this group will likely heighten the demand for biopsy procedures. As the global population ages, with over 703 million individuals aged 65 and above, cancer remains a pressing public health issue. By 2050, cancer incidence among those aged 85 and above is projected to increase fourfold, highlighting the need for continued focus on cancer control and treatment.

Rising infection risks restraints the Biopsy Devices market

Biopsy procedures help radiologists and surgeons assess abnormalities at specific sites, but they carry the risk of infections due to the incisions made to collect tissue samples. According to a 2014 article in The Journal of Urology (official journal of the American Urological Association), Sweden has seen an increase in severe post-prostate biopsy infections. The study found that urinary tract infections occurred in about 2% of cases, rising to 6% within 30 days of the biopsy, with 1% of patients requiring hospitalization. This elevated risk of infections following biopsy procedures could impede market growth.

Ongoing advancements in biopsy device technologies are creating opportunities for more accurate and less invasive procedures

Techniques such as ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans have become essential for guiding biopsies. For example, real-time ultrasound imaging allows healthcare professionals to precisely target and extract tissue samples, reducing the risk of complications. The growth of liquid biopsy technologies, which detect cancer-related biomarkers in blood or other bodily fluids, also shows significant promise for non-invasive cancer diagnosis and monitoring. Companies like TrovaGene and Natera are developing novel liquid biopsy tests for early colorectal and ovarian cancer detection, respectively. These innovations have the potential to enhance the precision, safety, and effectiveness of liquid biopsies, with continuous breakthroughs expected in this dynamic field.

Competitive Landscape

The Biopsy Devices market is characterized by the presence of several key players and a dynamic environment driven by technological advancements and innovation. Major companies, including Medtronic, Boston Scientific, and BD (Becton, Dickinson and Company), lead the market with their extensive portfolios and cutting-edge biopsy technologies. These firms focus on developing minimally invasive, precise, and user-friendly devices to meet the growing demand for accurate diagnostic procedures. Additionally, the market sees active participation from emerging players and startups, contributing to increased competition and innovation. Strategic partnerships, acquisitions, and collaborations are common strategies employed by companies to enhance their market presence and expand their product offerings.

The key players in the global Biopsy Devices market include - Danaher Corporation, CONMED Corporation, Cook Medical, DTR Medical, INRAD Inc., Devicor Medical Products Inc., Gallini Srl, TransMed7 LLC, Cardinal Health Inc., Hologic Inc. among others.

Recent Market Developments

Single Pass Receives FDA Approval for Kronos Biopsy Closure Device

• In April 2024, Single Pass received FDA approval for its Kronos biopsy closure device, classified as a Class II medical device

Argon Medical Devices Launches SuperCore Advantage Semi-Automatic Biopsy Instrument

• In May 2023, Argon Medical Devices launched the SuperCore Advantage, a semi-automatic biopsy instrument designed for soft tissue biopsy in the U.S

TransMed7 Plans to Introduce U.S.-Guided Biopsy Devices

• In February 2023, TransMed7 announced its intention to roll out its U.S.-guided biopsy devices

Devicor Medical Products Introduces Mammotome DualCore Biopsy System

• In August 2022, Devicor Medical Products, Inc. introduced the Mammotome DualCore Dual Stage Core Biopsy System, which is anticipated to enhance the company's biopsy device portfolio

The global Biopsy Devices market can be categorized as Product, Guidance Technique,

Application, End User and Region.